Category: Technology Licenses
Created On: 2022-04-28
Record Count: 18
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 2759
The Licensee has developed and produced the first FDA – approved electronically controlled transdermal drug delivery system that transports drugs through the skin comfortably, without needles. Our active transdermal drug delivery technology is based on a process known as electrotransport, or more specifically iontophoresis, a process that transports drugs, including peptides, through the skin by applying a low-level electrical current. Our active patch patented technology works by applying a charge to the drug-holding reservoir of the patch. This process differs significantly from passive transdermal drug delivery which relies on the slow, steady diffusion of drugs through the skin. A significantly greater number of drugs can be delivered through active transdermal delivery than is possible with passive transdermal delivery. Based on our analysis thus far, we estimate that there are currently over 220 FDA-approved drugs that may be delivered through our active transdermal delivery platform.
IPSCIO Record ID: 570
The technology refers to certain intellectual property encompassing a new type of non-invasive drug delivery system more commonly known as a transdermal patch.
Passive drug delivery patches have applications including smoking cessation (nicotine), birth control and hormone replacement therapy (estradiol), and angina (nitroglycerine). By contrast, active transdermal drug delivery systems allow certain drugs to be delivered through the skin many times faster than passive transdermal patches.
IPSCIO Record ID: 273586
Licensor is knowledgeable in the development of drug specific oral and transdermal dosage forms and has developed a unique range of delivery systems designed to provide newer and better formulations of medicaments.
Catapres-TTS (clonidine) transdermal therapeutic system is a square, tan adhesive patch containing an active blood-pressure-lowering medication. It is designed to deliver the drug into the body through the skin smoothly and consistently for one full week.
IPSCIO Record ID: 256229
For the License to Product, Licensor grants an exclusive license under the Licensed Technology, other than specific third party patents, solely to make, have made, use, import, sell, offer for sale and otherwise develop and Commercialize Products in the Field in the Territory, and, as permitted, an exclusive sublicense under Licensors license to Licensee Patents solely to make, have made, use, import, sell, offer for sale and otherwise Develop and Commercialize Products that contain bupivacaine, and no other Bupivacaine compound as the sole active ingredient, in the Field in the Territory.
Licensor grants to a limited right to use the trademark 'TRANSDURÂ®' solely in connection with the sale and marketing of Products in the Field within the Territory in accordance with this Agreement.
Bupivacaine shall mean bupivacaine, or any enantiomer, polymorph, salt form, racemate, isomer, diastereomer, tautomer, solvate, hydrate, or ester of bupivacaine.
Product shall mean any transdermal patch containing Bupivacaine as the sole active ingredient, including EladurÂ® as further described in IND No. 75,436.
TRANSDURÂ® Technology is defined as pharmaceutical transdermal patch drug delivery systems for use with a range of pharmaceutical preparations for sustained release of medication into the body, wherein the transdermal patch comprises a backing layer; a pressure-sensitive adhesive layer; and a release liner, wherein the pressure-sensitive adhesive layer comprises active agent, polyisobutylene, and plasticizer.
ELADUR is an investigational transdermal drug patch intended to deliver bupivacaine for up to 3 days from a single application.
Bupivacaine is an anesthetic (numbing medicine) that blocks nerve impulses in your body. Bupivacaine is used as a local (in only one area) anesthetic. Bupivacaine is given as an epidural injection into the spinal column to produce numbness during labor, surgery, or certain medical procedures.
Postherpetic neuralgia s the most common complication of shingles. The condition affects nerve fibers and skin, causing burning pain that lasts long after the rash and blisters of shingles disappear. The chickenpox (herpes zoster) virus causes shingles. Postherpetic neuralgia is a painful condition that affects your nerves and skin. It is a complication of herpes zoster, commonly called shingles. When the pain caused by shingles doesn't go away after the rash and blisters clear up, the condition is called postherpetic neuralgia.
IPSCIO Record ID: 233493
The Licensor of Bermuda grants to the Licensee of Bermuda an exclusive license to the Licensors Background Technology and Licensors Improvements to package, import, use, offer for sale and sell and otherwise distribute the Product for the Field in the Territory.
Licensor also grants a non-exclusive license in the Territory to use the Licensors Trademark solely for the purposes of exercising its rights and performing its obligations under this Agreement.
The Compound shall mean any formulations of Desferoxamine and any of its analogues, isomers or derivatives.
The System shall mean the ambulatory subcutaneous infusion drug delivery system for direct attachment to the body of a patient having a flexible diaphragm drug reservoir, which is capable of delivering factory pre-programmed continuous amounts of drug upon activation as disclosed and described in the Licensors patents.
Deferoxamine (DFOA) is a medication that binds iron and aluminium. It is specifically used in iron overdose, hemochromatosis either due to multiple blood transfusions or an underlying genetic condition, and aluminium toxicity in people on dialysis. It is used by injection into a muscle, vein, or under the skin.
IPSCIO Record ID: 28610
The Accudelâ„¢ Topical Drug Delivery System is a patented formulation which provides transdermal delivery of high percentage formulations of drugs, both small and large molecules, by a route that avoids first pass metabolism and significant systemic exposure. Accudelâ„¢ contains penetration enhancers which function synergistically to provide for rapid, but controllable transport of an active medication from the Accudel cream onto the skin and into the underlying soft tissue.
Accudelâ„¢ is biodegradable and has low toxicity. Accudel is made of non-immunogenic components, is thermodynamically stable and is quickly absorbed, as well as being aesthetically pleasing to many.
IPSCIO Record ID: 204556
Biphasixâ„¢ is a needle-free, noninvasive, particulate drug delivery system suitable for intra- and transdermal delivery of drugs.
BiPhasixâ„¢ can entrap and transport pharmaceutical products through the skin to achieve therapeutic benefit in a wide range of indications. Studies have shown that BiPhasixâ„¢ can significantly enhance the bioavailability of many drugs, leading to improved clinical outcomes. In addition, this proprietary technology can serve as an alternative dosage form to injectables by providing less invasive routes of administration such as dermal, transdermal, nasal, vaginal, ocular, and rectal.
The Company will use for the delivery and commercialization of cannabinoid, cannabidiol and tetrahydrocannabinol-based products.
IPSCIO Record ID: 372446
The Licensee acknowledges Licensors role as the co-inventor of the invention and therefore that she had a right to be the co-owner of the patent and its international extensions which protect the device for the intraocular transfer of active substances by iontophoresis.
By this agreement, Licensor of France renounces her right to take action against the Licensee of the Netherlands for recovery of the registered patents.
Certain patents with respect to and which are used in Licensee's EGP-437 Combination Product.
US patent application NÂ°09/225,206 (now granted, NÂ° 6,154,671)
Iontophoresis is a process of transdermal drug delivery by use of a voltage gradient on the skin.
EGP-437 in clinical trials, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues though our proprietary innovative drug delivery system, the EyeGateÂ® II Delivery System.
The EyeGateÂ® II Delivery System and EGP-437, are designed to address two major issues in ophthalmic medicine lack of patient compliance and safety. The EyeGateÂ® II Delivery System features a compact, elegant, and easy-to-use device that we believe has the potential to deliver drugs non-invasively and quickly into the ocular tissues through the use of iontophoresis, which can accelerate the onset of action, dramatically reduce treatment frequency versus eye drops and sustain therapeutic effect. Iontophoresis employs the use of a low electrical current that promotes the migration of a charged drug substance across biological membranes.
IPSCIO Record ID: 329732
The Parties shall undertake a Development Program with the Overall objective of obtaining all FDA approvals necessary for the commercialization of the Product.
Each party shall be the sole owner of the Technical Information of which only its employees and third party contractors arc inventors during the term of this Agreement. the Parties will jointly own the Technical Information of which both parties employees or contractors are joint inventors during the term of this agreement.
This agreement contains grants and grants back, exclusive and non-exclusive between the paries.
Product shall mean an oxybutynin patch, the AB-rated generic equivalent of OxytrolÂ®.
Oxybutynin transdermal patches are used to treat an overactive bladder (a condition in which the bladder muscles contract uncontrollably and cause frequent urination, urgent need to urinate, and inability to control urination). Oxybutynin is in a class of medications called antimuscarinics. It works by relaxing the bladder muscles.
Licensee is in the business of developing and manufacturing pharmaceutical products Licensee is a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products including transdermal and transmucosal delivery systems.
IPSCIO Record ID: 145984
IPSCIO Record ID: 26398
IPSCIO Record ID: 6128
IPSCIO Record ID: 5413
Patent No. 4,948,587, August 14, 1990 â€œUltrasound Enhancement of Transbuccal Drug Deliveryâ€
Patent No. 4,780,212, Issued October 25, 1988 â€œUltrasound Enhancement of Membrane Permeabilityâ€
Patent No. 4,948,587, August 14, 1990 â€œUltrasound Enhancement of Transbuccal Drug Deliveryâ€
U.S.S.N. 08/507,060, Filed July 25, 1995 â€œTransdermal Protein Delivery Using Low-Frequency Sonophoresisâ€
U.S.S.N. 08/511,583, Filed August 4, 1995
U.S.S.N. 08/545,236, Filed October 19, 1995 â€œTransdermal Protein Delivery or Measurement Using Low-Frequency Sonophoresisâ€
IPSCIO Record ID: 203450
(a) the Licensor Patents and Technology; and
(b) Licensors rights in any Joint Developments in the Field;
in each case to develop, use, make, have made, sell or otherwise dispose of the Products in the Field; provided, however, that notwithstanding the foregoing, Licensee shall not have the right to make or have made the Products other than as expressly contemplated by or provided in the Manufacturing and Supply Agreement, or to modify in any way the structure or composition of the Products, without the prior written consent of Licensor.
Products means the TE Patch and the T-Patch. For the avoidance of doubt, Products does not include Intrinsa.
The Once A Week T Patch means the transdermal patch drug delivery system to be developed by Licensor that will contain testosterone as the single active ingredient at a dosage in vitro of testosterone to be determined, that is intended to be worn for seven consecutive days, which shall be evidenced by either an NDA or a supplement to the NDA for the T Patch or lntrinsa.
The T-Patch means the transdermal patch drug delivery system developed by Licensor that contains testosterone as the single active ingredient at an in vivo dosage bio-equivalent to Intrinsa which is worn for three to four consecutive days, which shall be evidenced by either an NDA, a supplement thereto, or a supplement to the NDA, for Intrinsa, and shall include any minor improvements or modifications to such product that do not require additional development work.
The TE Patch means the transdermal patch drug delivery system to be developed by Licensor that will contain as the active ingredients a combination of testosterone and estrogen at a single dosage in vivo of testosterone to be determined, which dosage shall be in the range of about 50 to about 600 meg/day and which shall he evidenced by an NDA or a supplement thereto.
IPSCIO Record ID: 4876
IPSCIO Record ID: 367578
5,540,934 – Compositions for applying active substances to or through the skin
5,716,638 – Composition for applying active substances to or through the skin
Product means a pharmaceutical preparation or composition containing the Drug Formulation which is covered by a Valid Patent Claim.
Drug means the Licensees organoselenium drug or materials, as specified in this Agreement, and its racemate, metabolite, derivatives, isomers, polymorphs, crystals.
Drug Formulation means the formulation of the Drug utilizing Licensors Formulation Technology.
Ethosomes are phospholipid nanovesicles used for dermal and transdermal delivery of molecules.
IPSCIO Record ID: 260368
— an exclusive license, even as to Licensor, under the Licensed Patents to make, have made, import, use, sell, offer for sale and have sold Products in the Field in the Territory, subject to rights already granted to a Third Party under the Development Agreement between Licensor and and the Third Party; and,
— a non-exclusive royalty-free license under the Future Licensor Patents to make, have made, import, use, sell, offer for sale and have sold Products in the Field in the Territory.
Licensor will assign to Licensee the Trademarks.
The Trademark means the trademark applications and registrations for the mark MACROFLUX.
Microprojection System means a microprojection array having a plurality of microprojections which pierce at least through the outmost layer, i.e., the stratum comeum layer, of the skin.
MacrofluxÂ® transdermal microprojection delivery system provides unique benefits including convenient needle-free administration with room temperature stability for various therapeutic peptides, proteins, small molecules and vaccines.
skin patch technology provides rapid and reproducible intracutaneous administration of dry-coated antigen. The depth of skin penetration targets skin immune cells; the quantity of antigen delivered can be controlled by formulation, patch wearing time, and system size. This novel needle-free patch technology may ultimately have broad applications for a wide variety of therapeutic vaccines to improve efficacy and convenience of use.
IPSCIO Record ID: 1724